According to the data, around 38.8 percent of girls aged 12 received the HPV vaccine in Italy in 2022. Friuli Venezia Giulia was the region with the lowest figure, with an immunization rate of only 0.7 percent for the considered population. This statistic depicts the human papillomavirus (HPV) immunization rate among female aged 12 years in Italy in 2022, by region.

Series Name: Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis human papillomavirus (HPV) (percent)Series Code: SH_ACS_HPVRelease Version: 2020.Q2.G.03 This dataset is the part of the Global SDG Indicator Database compiled through the UN System in preparation for the Secretary-General's annual report on Progress towards the Sustainable Development Goals.Indicator 3.b.1: Proportion of the target population covered by all vaccines included in their national programmeTarget 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for allGoal 3: Ensure healthy lives and promote well-being for all at all agesFor more information on the compilation methodology of this dataset, see https://unstats.un.org/sdgs/metadata/

This dataset presents the footprint of the percentage of boys who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2014-2016 and is aggregated to …Show full descriptionThis dataset presents the footprint of the percentage of boys who were fully immunised against human papillomavirus (HPV). The data spans the financial years 2014-2016 and is aggregated to Statistical Area Level 4 (SA4) geographic boundaries from the 2011 Australian Statistical Geography Standard (ASGS). HPV is a common sexually transmitted infection. It is estimated that more than four out of five people will have an HPV infection at some point in their lives. Although often asymptomatic, HPV infection can cause a wide range of cancers, including cervical cancer, and other conditions such as genital warts. The Australian Government introduced the school-based National HPV Vaccination Program in 2007 for adolescent girls, and extended it to include boys in January 2013. The data were sourced from the National HPV Vaccination Program Register (HPV Register), which is operated by the Victorian Cytology Service. The HPV Register records information about HPV vaccine doses administered under the National HPV Vaccination Program in Australia. The data reported are for girls and boys aged 15 who had received three doses of HPV vaccine by 30 June 2016 (as at 12 August 2017). The Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) for females and males aged 13 at 30 June 2014 was used for the denominator, as this reflects the eligible population at the time most vaccinations were administered. For further information about this dataset, visit the data source: Australian Institute of Health and Welfare - HPV immunisation rates in 2015-16 Data Tables. Please note: AURIN has spatially enabled the original data. These data include boys aged 15 who had received three doses of HPV vaccine by 30 June 2015 and 2016. Any doses administered after that date are not included and therefore the current coverage in this cohort may be higher than reported here. Only vaccinations reported to the National HPV Vaccination Program Register (HPV Register) are included. Boys whose courses are considered to be incomplete according to the Chief Medical Officer guidelines and boys who do not wish their details to be recorded on the HPV Register are excluded. Copyright attribution: Government of the Commonwealth of Australia - Australian Institute of Health and Welfare, (2017): ; accessed from AURIN on 12/3/2020. Licence type: Creative Commons Attribution 3.0 Australia (CC BY 3.0 AU)

Cervical Cancer Risk Factors for Biopsy: This Dataset is Obtained from UCI Repository and kindly acknowledged! This file contains a List of Risk Factors for Cervical Cancer leading to a Biopsy Examination! About 11,000 new cases of invasive cervical cancer are diagnosed each year in the U.S. However, the number of new cervical cancer cases has been declining steadily over the past decades. Although it is the most preventable type of cancer, each year cervical cancer kills about 4,000 women in the U.S. and about 300,000 women worldwide. In the United States, cervical cancer mortality rates plunged by 74% from 1955 - 1992 thanks to increased screening and early detection with the Pap test. AGE Fifty percent of cervical cancer diagnoses occur in women ages 35 - 54, and about 20% occur in women over 65 years of age. The median age of diagnosis is 48 years. About 15% of women develop cervical cancer between the ages of 20 - 30. Cervical cancer is extremely rare in women younger than age 20. However, many young women become infected with multiple types of human papilloma virus, which then can increase their risk of getting cervical cancer in the future. Young women with early abnormal changes who do not have regular examinations are at high risk for localized cancer by the time they are age 40, and for invasive cancer by age 50. SOCIOECONOMIC AND ETHNIC FACTORS Although the rate of cervical cancer has declined among both Caucasian and African-American women over the past decades, it remains much more prevalent in African-Americans -- whose death rates are twice as high as Caucasian women. Hispanic American women have more than twice the risk of invasive cervical cancer as Caucasian women, also due to a lower rate of screening. These differences, however, are almost certainly due to social and economic differences. Numerous studies report that high poverty levels are linked with low screening rates. In addition, lack of health insurance, limited transportation, and language difficulties hinder a poor woman’s access to screening services. HIGH SEXUAL ACTIVITY Human papilloma virus (HPV) is the main risk factor for cervical cancer. In adults, the most important risk factor for HPV is sexual activity with an infected person. Women most at risk for cervical cancer are those with a history of multiple sexual partners, sexual intercourse at age 17 years or younger, or both. A woman who has never been sexually active has a very low risk for developing cervical cancer. Sexual activity with multiple partners increases the likelihood of many other sexually transmitted infections (chlamydia, gonorrhea, syphilis).Studies have found an association between chlamydia and cervical cancer risk, including the possibility that chlamydia may prolong HPV infection. FAMILY HISTORY Women have a higher risk of cervical cancer if they have a first-degree relative (mother, sister) who has had cervical cancer. USE OF ORAL CONTRACEPTIVES Studies have reported a strong association between cervical cancer and long-term use of oral contraception (OC). Women who take birth control pills for more than 5 - 10 years appear to have a much higher risk HPV infection (up to four times higher) than those who do not use OCs. (Women taking OCs for fewer than 5 years do not have a significantly higher risk.) The reasons for this risk from OC use are not entirely clear. Women who use OCs may be less likely to use a diaphragm, condoms, or other methods that offer some protection against sexual transmitted diseases, including HPV. Some research also suggests that the hormones in OCs might help the virus enter the genetic material of cervical cells. HAVING MANY CHILDREN Studies indicate that having many children increases the risk for developing cervical cancer, particularly in women infected with HPV. SMOKING Smoking is associated with a higher risk for precancerous changes (dysplasia) in the cervix and for progression to invasive cervical cancer, especially for women infected with HPV. IMMUNOSUPPRESSION Women with weak immune systems, (such as those with HIV / AIDS), are more susceptible to acquiring HPV. Immunocompromised patients are also at higher risk for having cervical precancer develop rapidly into invasive cancer. DIETHYLSTILBESTROL (DES) From 1938 - 1971, diethylstilbestrol (DES), an estrogen-related drug, was widely prescribed to pregnant women to help prevent miscarriages. The daughters of these women face a higher risk for cervical cancer. DES is no longer prsecribed.

Additional file 2. Detailed data for each sample, including archive type, tissue type, histological subtype, collection year, details for partial consent validation ("Consent Notes"), patient age at sample collection, reported race, percentage of off-target human reads, overall HPV status (“unclear” indicates a high fraction of human reads, “qPCR filter” indicates a low amplified DNA concentration), HPV genotype assignments (using a 20% read fraction threshold and other standard criteria defined in the Methods), percentages of specific HPV genotype reads, previous archived DNA genotyping results (based on RFLP analysis), amplified DNA concentrations (quantified by qPCR after gel extraction), median and maximum sizes among human-aligned reads (calculated from paired-end reads using Picard), paired sample IDs (based on provided annotations, QC Array IBD calculations, or both), QC Array call rate (a QC measure for the sample), primary super-population assignments (based on >50% estimated contributions, using ADMIXTURE), mixed super-population assignments (based on >20% estimated contributions, ADMIXTURE), distance-based bootstrap super-population assignments (with confidence >95%), HPV L1 amplicon sequencing barcode, run information (run number: flowcell ID: lane number), and total HPV L1 amplicon sequencing reads (combined between lanes).

According to a survey that was conducted in August 2023 in Japan, over 41 percent of women said that they knew about the HPV vaccine. The share was much lower among men.

Coverage of DTP containing vaccine (3rd dose): Percentage of surviving infants who received the 3 doses of diphtheria and tetanus toxoid with pertussis containing vaccine in a given year. Coverage of Measles containing vaccine (2nd dose): Percentage of children who received two dose of measles containing vaccine according to nationally recommended schedule through routine immunization services in a given year. Coverage of Pneumococcal conjugate vaccine (last dose in the schedule): Percentage of surviving infants who received the nationally recommended doses of pneumococcal conjugate vaccine in a given year. Coverage of HPV vaccine (last dose in the schedule): Percentage of 15 years old girls received the recommended doses of HPV vaccine. Currently performance of the program in the previous calendar year based on target age group is used.

Awareness of cervical cancer among participant women (n = 337) aged 21–49 years, Amhara region, Ethiopia, 2019.

Dataset from Singapore Department of Statistics. For more information, visit https://data.gov.sg/datasets/d_5931c645b472d2a4604cffa729e18309/view

Series Name: (S.4.C.13) Extent to which countries have laws and regulations that guarantee full and equal access to women and men aged 15 years and older to sexual and reproductive health care information and education: Component 13: HPV Vaccine (percent)Series Code: SH_LGR_ACSRHEC13Release Version: 2020.Q2.G.03 This dataset is the part of the Global SDG Indicator Database compiled through the UN System in preparation for the Secretary-General's annual report on Progress towards the Sustainable Development Goals.Indicator 5.6.2: Number of countries with laws and regulations that guarantee full and equal access to women and men aged 15 years and older to sexual and reproductive health care, information and educationTarget 5.6: Ensure universal access to sexual and reproductive health and reproductive rights as agreed in accordance with the Programme of Action of the International Conference on Population and Development and the Beijing Platform for Action and the outcome documents of their review conferencesGoal 5: Achieve gender equality and empower all women and girlsFor more information on the compilation methodology of this dataset, see https://unstats.un.org/sdgs/metadata/

According to October 2023 data, ** percent of the respondents were of the opinion that the human pappiloma virus, or HPV vaccine is very effective. A further ** percent believed that it was somewhat effective. This statistic illustrates the distribution of Americans opinion on HPV vaccine in 2022 and 2023.

Demographic characteristics and awareness of young adults and parents/guardians about HPV and HPV vaccine.

In Denmark, younger generations of the population were vaccinated against HPV to a greater extent than the older generations. As of 2018, 92 percent of Danish females between 15 and 24 years had been vaccinated against HPV at least once. For males in the same age group, the share of respondents amounted to 62 percent. In the older age groups, vaccinations were less common, and more women had had the vaccine than men.

In Denmark, free HPV vaccines are provided for girls when they turn 12 years. As of September 2019, the vaccine was also offered for boys turning 12 years.

Demographic characteristics of participant women (n = 337) aged 21–49 years, Amhara region, Ethiopia, 2019.

Sociodemographic and behavioural characteristics of the study participants.

Hypothetical health state scenarios relating to genital HPV infection and cervical cancer, ranks and percentages of perfect health by six health states lasting 12 months, standard gamble utility scores and intra-class correlation coefficient for cervical cancer duration among Indigenous women.

Prevalence of HPV (16/18) infections among participant women (n = 337) aged 21–49 years, with and without cervical lesions, Amhara region, Ethiopia, 2019.

Opinion about HPV vaccination after pharmacy counseling service and source of information.

In 2021, about 5.8 thousand sexually transmitted infections (STIs) were reported in Italy, almost 18 percent more than the ones recorded during 2020. According to the data, most of the cases of diagnosed STIs were caused by bacterial and viral infections, with roughly 2.9 thousand and 2.8 thousand cases, respectively. People aged between 25 and 44 were the most affected.

HIV infection Among sexually transmitted infections caused by viruses, the most notorious is HIV, for which new cases in Italy have decreased over the past decade, from 3,892 new diagnoses in 2011 to 1,770 in 2021. The main reasons for conducting an HIV test were, in most of the cases, related to having symptoms of the disease and secondly to having had sexual intercourse without a condom.

Human papillomavirus The human papillomavirus (HPV) is a very common infectious virus, that can be associated with some types of cancers, among which cervical cancer is the most frequent. A vaccine against HPV is available and protects from the most serious variants of the virus.

Awareness of the HPV and the HPV vaccination among male and female young adults and parents/guardians of boys and girls.